GlassScriptPhysician profile
Celia Martini
NPI 1215581152
$3,264.61
in general payments reported to CMS, 2019-2025
20 companies · $958 in 2025
The $958 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $378 · 2023: $389 · 2024: $1,246 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $633.89 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $411.20 | 2022-2025 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $305.45 | 2023-2025 | Cobalt Dr Mri Surescan, Micra, Linq II |
| Edwards Lifesciences Corporation | $278.92 | 2025 | |
| Janssen Pharmaceuticals, INC | $262.19 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.35 | 2021-2025 | Jardiance |
| Pfizer INC. | $237.41 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $168.68 | 2022-2024 | Opsumit, Uptravi |
| Abiomed | $125.02 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $108.83 | 2021-2025 | Wainua, Farxiga |
| Abbott Laboratories | $106.26 | 2024-2025 | Amplatzer Amulet, Amplatzer, Aveir |
| E.R. Squibb & Sons, L.L.C. | $88.23 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $58.43 | 2022-2025 | Repatha |
| Merck Sharp & Dohme LLC | $57.29 | 2023-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $50.48 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.29 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $28.75 | 2024 | Arcalyst |
| Biotronik INC. | $20.56 | 2021 | |
| Cardiva Medical, INC. | $19.92 | 2023 | Cardiva Vascade 6/7f Vcs |
| Amarin Pharma, INC. | $18.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Martini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.